Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS
Publication date: Available online 6 November 2014 Source:Pulmonary Pharmacology & Therapeutics Author(s): M. Latorre , F. Novelli , B. Vagaggini , F. Braido , A. Papi , A. Sanduzzi , P. Santus , N. Scichilone , P. Paggiaro Inhaled corticosteroids (ICS) are frequently recommended for the treatment of asthma and COPD, often in combination with long-acting beta2-agonists (LABA), depending on the severity of the disease and/or on the specific phenotype. Several ICS/LABA combinations are currently available that differ in their pharmacokinetic characteristics and dose of both components. Thus, this review assesses differences in the efficacy and the safety profiles of the ICS components in the two more frequently used ICS/LABA combinations (budesonide/formoterol and fluticasone/salme...